Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As India's Exports Take Off, Building Brand India Will Be Key Focus, Says Government

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Building "Brand India" to boost the pharmaceutical trade will be a key priority for the Indian government as estimates suggest that exports of finished products and raw materials from India could more than double to $20 billion by 2015

You may also be interested in...



Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania

TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania

With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub

MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries

India Proposes Big Push To Pharma Manufacturing And Research; Talks On With Multinational Companies For Vaccine Development Center

MUMBAI - The Indian government is moving swiftly on a series of new initiatives that seek to position India as a country of choice for big pharmaceutical companies looking to establish research centers and build manufacturing facilities. An outlay of $1 to $2 billion will be made every year through 2020 for the comprehensive action plan, if implemented

Related Content

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel